Associations between XRCC1-Arg399Gln polymorphism and the risk of prostate cancer: an updated meta-analysis

IF 2.4 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Amino Acids Pub Date : 2025-09-18 DOI:10.1007/s00726-025-03475-0

Jiang Deng, Lihua Xu, Jun Zhou, He Huang

{"title":"Associations between XRCC1-Arg399Gln polymorphism and the risk of prostate cancer: an updated meta-analysis","authors":"Jiang Deng, Lihua Xu, Jun Zhou, He Huang","doi":"10.1007/s00726-025-03475-0","DOIUrl":null,"url":null,"abstract":"<div><p>The X-ray repair cross-complementary group 1 (XRCC1) gene 399 codon polymorphism may alter the structure of DNA repair enzymes to regulate DNA repair capacity. Impaired DNA repair ability can lead to the development of cancers such as prostate cancer (PCa). Although the association between the XRCC1 codon 399 polymorphism and the risk of PCa has been widely reported, the results have not been clear. Data were collected from PubMed, EMBASE, the Wanfang Database, CNKI and the Web of Science. A total of 20 case‒control studies were selected for inclusion in this updated analysis to determine the association between the XRCC1 codon 399 polymorphism and the risk of PCa. The crude odds ratio (OR) and 95% confidence interval (CI) were calculated using Stata (version 18) software to evaluate the association between the XRCC1-Arg399Gln polymorphism and prostate cancer. We identified 20 eligible reports that included 5803 cases of prostate cancer and 5470 controls. Our meta-analysis revealed a significant association between the XRCC1-Arg399Gln polymorphism and the risk of prostate cancer. In particular, according to the recessive models, this polymorphism was associated with a significantly increased prevalence of prostate cancer in Asian populations (AA versus AG + GG: OR = 1.255, 95% CI = 1.063–1.481, <i>P</i> = 0.507, I<sup>2</sup>, < 25%). Based on these results, the XRCC1-Arg399Gln polymorphism may be a risk factor for prostate cancer and can be used as a biomarker to predict the prognosis of prostate cancer.</p></div>","PeriodicalId":7810,"journal":{"name":"Amino Acids","volume":"57 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00726-025-03475-0.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amino Acids","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1007/s00726-025-03475-0","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The X-ray repair cross-complementary group 1 (XRCC1) gene 399 codon polymorphism may alter the structure of DNA repair enzymes to regulate DNA repair capacity. Impaired DNA repair ability can lead to the development of cancers such as prostate cancer (PCa). Although the association between the XRCC1 codon 399 polymorphism and the risk of PCa has been widely reported, the results have not been clear. Data were collected from PubMed, EMBASE, the Wanfang Database, CNKI and the Web of Science. A total of 20 case‒control studies were selected for inclusion in this updated analysis to determine the association between the XRCC1 codon 399 polymorphism and the risk of PCa. The crude odds ratio (OR) and 95% confidence interval (CI) were calculated using Stata (version 18) software to evaluate the association between the XRCC1-Arg399Gln polymorphism and prostate cancer. We identified 20 eligible reports that included 5803 cases of prostate cancer and 5470 controls. Our meta-analysis revealed a significant association between the XRCC1-Arg399Gln polymorphism and the risk of prostate cancer. In particular, according to the recessive models, this polymorphism was associated with a significantly increased prevalence of prostate cancer in Asian populations (AA versus AG + GG: OR = 1.255, 95% CI = 1.063–1.481, P = 0.507, I², < 25%). Based on these results, the XRCC1-Arg399Gln polymorphism may be a risk factor for prostate cancer and can be used as a biomarker to predict the prognosis of prostate cancer.

查看原文本刊更多论文

XRCC1-Arg399Gln多态性与前列腺癌风险之间的关系：一项最新的荟萃分析

x射线修复交叉互补组1 （XRCC1）基因399密码子多态性可能改变DNA修复酶的结构，从而调节DNA修复能力。受损的DNA修复能力会导致前列腺癌（PCa）等癌症的发展。虽然XRCC1密码子399多态性与PCa风险之间的关联已被广泛报道，但结果尚不清楚。数据来源于PubMed、EMBASE、万方数据库、中国知网和Web of Science。本次更新的分析共纳入了20项病例对照研究，以确定XRCC1密码子399多态性与PCa风险之间的关系。采用Stata （version 18）软件计算粗比值比（OR）和95%置信区间（CI），评价XRCC1-Arg399Gln多态性与前列腺癌的相关性。我们确定了20份符合条件的报告，包括5803例前列腺癌病例和5470例对照。我们的荟萃分析显示XRCC1-Arg399Gln多态性与前列腺癌风险之间存在显著关联。特别是，根据隐性模型，这种多态性与亚洲人群中前列腺癌患病率的显著增加有关（AA与AG + GG: OR = 1.255, 95% CI = 1.063-1.481, P = 0.507, I2, < 25%）。基于这些结果，XRCC1-Arg399Gln多态性可能是前列腺癌的危险因素，可作为预测前列腺癌预后的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Amino Acids 生物-生化与分子生物学

CiteScore

6.40

自引率

5.70%

发文量

审稿时长

2.2 months

期刊介绍： Amino Acids publishes contributions from all fields of amino acid and protein research: analysis, separation, synthesis, biosynthesis, cross linking amino acids, racemization/enantiomers, modification of amino acids as phosphorylation, methylation, acetylation, glycosylation and nonenzymatic glycosylation, new roles for amino acids in physiology and pathophysiology, biology, amino acid analogues and derivatives, polyamines, radiated amino acids, peptides, stable isotopes and isotopes of amino acids. Applications in medicine, food chemistry, nutrition, gastroenterology, nephrology, neurochemistry, pharmacology, excitatory amino acids are just some of the topics covered. Fields of interest include: Biochemistry, food chemistry, nutrition, neurology, psychiatry, pharmacology, nephrology, gastroenterology, microbiology